Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.

NCT Number	NCT07389525
Lead Sponsor	Indiana University
Conditions	Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Enrollment	80 participants
Start Date	2026-09
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-15